Thanacoody R H
Consultant Physician and Clinical Pharmacologist, Wolfson Unit of Clinical Pharmacology, Newcastle University, UK.
Recent Pat Antiinfect Drug Discov. 2011 May;6(2):92-8. doi: 10.2174/157489111796064588.
Thioridazine is a phenothiazine drug which has previously been extensively used for its antipsychotic properties as it is associated with a low risk of extra-pyramidal side-effects. There is good evidence to suggest that, in common with other phenothiazine drugs, thioridazine has important anti-microbial activity and is a potential candidate for development as an anti-microbial drug against multi-resistant organisms, including drug-resistant strains of M. tuberculosis. The clinical pharmacology and toxicity profile of thioridazine are reviewed in this article and the implications for future drug development along with the patent are discussed.
硫利达嗪是一种吩噻嗪类药物，因其抗精神病特性，过去曾被广泛使用，因为它与锥体外系副作用的风险较低有关。有充分证据表明，与其他吩噻嗪类药物一样，硫利达嗪具有重要的抗菌活性，是开发针对多重耐药菌（包括耐药结核分枝杆菌菌株）的抗菌药物的潜在候选药物。本文综述了硫利达嗪的临床药理学和毒性概况，并讨论了其对未来药物开发的影响以及相关专利。
